Business
Axim® Biotechnologies Completes First Phase of Pharmacokinetic Clinical Study on Cannabinoid-Based Gum With Dronabinol
Axim® Biotechnologies Completes First Phase of Pharmacokinetic Clinical Study on Cannabinoid-Based Gum With Dronabinol.
About this update from Axim Biotechnologies, Inc.
[{"type":"text","content":"\n NEW YORK, Feb. 18, 2020 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and cannabinoid research, announced today that it has completed the first phase of its pharmacokinetic clinical study on its cannabinoid-based chewing gum with dronabinol, a synthetic form of tetrahydrocannabinol (THC). The multi-phase study is aimed to understand how cannabis may serve as a treatment for chemotherapy-related symptoms. The first phase of this study, consisting of 10 healthy human subjects, was performed at the Clinical Trial Center of AXIM’s contract research organization (\"CRO\") QPS Netherlands BV, a global leader in contract research, with regulatory support from ProPharma Group, a provider of regulatory compliance and medical information services. The study’s goal was to prove that dronabinol is successfully released from the gum. Each subject received a 5 mg dose of dronabinol in a chewing gum product and was instructed to chew the gum for 40 minutes. Preliminary results provided evidence that: All subjects showed a release of dronabinol starting at 10 minutes, providing evidence of oral mucosal absorptionIn more than half of the study’s subjects, the dronabinol pharmacokinetic profile reflected a sustained released effect for four hours after administration “We are excited to have completed the first phase of our clinical study and are optimistic about moving forward with the next phase,” said John W. Huemoeller II, Chief Executive Officer of AXIM® Biotech. “We are getting closer every day to proving that our unique delivery method can provide cancer patients with quicker and more efficient relief from their chemotherapy-related symptoms.” The Centers for Disease Control and Prevention (CDC) recently reported that 650,000 cancer patients in the U.S. receive chemotherapy in an outpatient oncology clinic each year. Chemotherapy, though it has been proven to be an effective treatment to kill cancer cells, causes damage to other cells and tissues in the body, often making patients experience many difficult symptoms such as a weakened immune system, pain, nausea, vomiting, and diarrhea. With ...